Novartis AG (SWX: NOVN)
Health Care · Pharmaceuticals · CH
CHF127.42
+0.85% today · +23.9% 1Y
Novartis AG (SWX: NOVN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $302.17B and employs 75,267 people.
Over the last twelve months the share price has gained 23.9%, trading between 96.03 and 131.50.
Tweenvest scores Novartis AG across four factors: quality 88/100, value 20/100, growth 60/100, dividend 90/100. Its strongest factor is dividend.
NOVN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $302.17B
- Revenue (TTM)
- $56.69B
- P/E
- 23.84
- EPS
- 6.61
- Dividend yield
- 2.93%
- Beta (5Y)
- 0.49
- 52-week high
- CHF131.50
- 52-week low
- CHF96.03
- Avg volume (3M)
- —
- Shares outstanding
- 1.90B
- Employees
- 75,267
- Next earnings
- —
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
- ISIN
- CH0012005267
- Founded
- 1996
- Listed since
- Mar 8, 1996
- Exchange
- SIX Swiss Exchange
- Currency
- CHF
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.75 | +0.19% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.56 | +0.66% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
| Bristol-Myers Squibb CompanyNYSE: BMY | $136.88B | $67.01 | +2.35% |
Figures last refreshed Aug 18, 2026.